Sino Biopharmaceutical (01177) to Acquire 95.09% Stake in LaNova Medicines

Stock Track

Jul 15, 2025

Sino Biopharmaceutical Limited (01177) announced on July 15, 2025, that its wholly-owned subsidiary, Zhengda Pharmaceutical Investment (Beijing) Group Co., Ltd., will acquire a 95.09% equity interest in LaNova Medicines. The transaction carries a maximum consideration of approximately US$951 million. After deducting LaNova's estimated cash and bank deposits of US$450 million at closing, the net payment required from the buyer amounts to roughly US$501 million.

Currently, the acquiring subsidiary holds a 4.91% stake in LaNova Medicines. Upon completion of the acquisition, Sino Biopharmaceutical will own 100% of LaNova, making it an indirect wholly-owned subsidiary.

LaNova Medicines represents a globally leading innovative drug R&D company specializing in tumor immunology and tumor microenvironment research. This strategic move substantially aligns with Sino Biopharmaceutical's innovation-driven and internationalization strategy. The acquisition is expected to significantly enhance the group's core competitiveness and global influence within the oncology innovation sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1114227457"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1114227457\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1114227457?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114227457","market":"us","top_or_hot":-1,"title":"Sino Biopharmaceutical (01177) to Acquire 95.09% Stake in LaNova Medicines","media":"Stock Track","content":"<p>Sino Biopharmaceutical Limited (01177) announced on July 15, 2025, that its wholly-owned subsidiary, Zhengda Pharmaceutical Investment (Beijing) Group Co., Ltd., will acquire a 95.09% equity interest in LaNova Medicines. The transaction carries a maximum consideration of approximately US$951 million. After deducting LaNova's estimated cash and bank deposits of US$450 million at closing, the net payment required from the buyer amounts to roughly US$501 million.</p>\n<p>Currently, the acquiring subsidiary holds a 4.91% stake in LaNova Medicines. Upon completion of the acquisition, Sino Biopharmaceutical will own 100% of LaNova, making it an indirect wholly-owned subsidiary.</p>\n<p>LaNova Medicines represents a globally leading innovative drug R&D company specializing in tumor immunology and tumor microenvironment research. This strategic move substantially aligns with Sino Biopharmaceutical's innovation-driven and internationalization strategy. The acquisition is expected to significantly enhance the group's core competitiveness and global influence within the oncology innovation sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical (01177) to Acquire 95.09% Stake in LaNova Medicines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical (01177) to Acquire 95.09% Stake in LaNova Medicines\n</h2>\n\n<h4 class=\"meta\">\n\n2025-07-15 18:40 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sino Biopharmaceutical Limited (01177) announced on July 15, 2025, that its wholly-owned subsidiary, Zhengda Pharmaceutical Investment (Beijing) Group Co., Ltd., will acquire a 95.09% equity interest ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"","article_id":"1114227457","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114227457","pubTimestamp":1752576032,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":null,"summary":"Sino Biopharmaceutical Limited (01177) announced on July 15, 2025, that its wholly-owned subsidiary, Zhengda Pharmaceutical Investment (Beijing) Group Co., Ltd., will acquire a 95.09% equity interest...","collect":0,"end_time":0,"defaultTopTitle":"laohu8.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1589":"北水核心资产","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1515":"抗疫概念","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","01177":"中国生物制药"},"translate_title":"中国生物制药(01177)将收购Lanova Medicines 95.09%股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"01177":1,"09939":1},"content_text":"Sino Biopharmaceutical Limited (01177) announced on July 15, 2025, that its wholly-owned subsidiary, Zhengda Pharmaceutical Investment (Beijing) Group Co., Ltd., will acquire a 95.09% equity interest in LaNova Medicines. The transaction carries a maximum consideration of approximately US$951 million. After deducting LaNova's estimated cash and bank deposits of US$450 million at closing, the net payment required from the buyer amounts to roughly US$501 million.\nCurrently, the acquiring subsidiary holds a 4.91% stake in LaNova Medicines. Upon completion of the acquisition, Sino Biopharmaceutical will own 100% of LaNova, making it an indirect wholly-owned subsidiary.\nLaNova Medicines represents a globally leading innovative drug R&D company specializing in tumor immunology and tumor microenvironment research. This strategic move substantially aligns with Sino Biopharmaceutical's innovation-driven and internationalization strategy. The acquisition is expected to significantly enhance the group's core competitiveness and global influence within the oncology innovation sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}